Biohaven (BHVN) VP & CAO reports RSU vesting, updates share holdings

Rhea-AI Filing Summary

Biohaven Ltd. VP and Chief Accounting Officer George C. Clark reported routine equity compensation activity. On January 5, 2026, 2,500 common shares were issued upon the vesting and settlement of a restricted share unit award at an exercise price of $0, increasing his directly held common shares to 68,095 before tax withholding.

On the same date, 1,117 common shares were withheld by Biohaven at a price of $9.93 to cover tax obligations related to the vesting; the footnote clarifies that no shares were sold into the market. After these transactions, Clark directly beneficially owned 66,978 common shares and indirectly owned 20,000 common shares through an IRA, along with 5,000 restricted share units representing rights to receive additional common shares, subject to continued service and future vesting dates.

Insider Trade Summary

2,500 shares exercised/converted

Mixed 4 txns

Insider Clark George C.

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Share Unit Award	2,500	$0.00	--
Exercise	Common Shares	2,500	$0.00	--
Tax Withholding	Common Shares	1,117	$9.93	$11K
holding	Common Shares	--	--	--

Holdings After Transaction: Restricted Share Unit Award — 5,000 shares (Direct); Common Shares — 68,095 shares (Direct); Common Shares — 20,000 shares (Indirect, By IRA)

Footnotes (1)

1. No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Each restricted share unit represents the contingent right to receive one common share of the Issuer. The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. Not applicable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark George C.

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/05/2026		M		2,500	A	$0	68,095	D
Common Shares	01/05/2026		F		1,117(1)	D	$9.93	66,978	D
Common Shares								20,000	I	By IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit Award	(2)	01/05/2026		M			2,500	(3)	(4)	Common Shares	2,500	$0(2)	5,000	D

Explanation of Responses:

1. No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.

2. Each restricted share unit represents the contingent right to receive one common share of the Issuer.

3. The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.

4. Not applicable.

Remarks:

	/s/ George Clark	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biohaven (BHVN) report for George C. Clark?

Biohaven reported that George C. Clark, its VP and Chief Accounting Officer, had 2,500 restricted share units vest on January 5, 2026, which settled into 2,500 common shares at an exercise price of $0.

Were any Biohaven (BHVN) shares sold by George C. Clark in this Form 4?

No open market sale occurred. A footnote states that the 1,117 common shares reported with transaction code F were withheld by the issuer at $9.93 per share solely to satisfy tax withholding requirements related to restricted share unit vesting.

How many Biohaven (BHVN) common shares does George C. Clark own after the reported transactions?

After the January 5, 2026 transactions, George C. Clark directly beneficially owned 66,978 common shares of Biohaven and indirectly owned 20,000 common shares through an IRA.

What derivative securities related to Biohaven (BHVN) does George C. Clark hold after this Form 4?

Following the vesting reported, George C. Clark held 5,000 restricted share units, each representing the contingent right to receive one Biohaven common share, subject to continued service and future vesting dates.

What is the vesting schedule of George C. Clark’s Biohaven (BHVN) restricted share units?

A footnote explains that Clark was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027, and 2028, contingent on his continued service with Biohaven at each vesting date.

What is the role of George C. Clark at Biohaven (BHVN) as disclosed in this filing?

The filing identifies George C. Clark as an officer of Biohaven Ltd., serving as VP, Chief Accounting Officer, and not as a director or 10% owner.